Literature DB >> 9100348

HIV-I protease. Cloning, expression, and purification.

N I Dergousova1, A M Volynskaya, L D Rumsh.   

Abstract

A new method for obtaining HIV-I protease was suggested. Fusion proteins composed of the N-terminal fragment of human gamma-interferon and HIV-I protease connected with (Asp)4Lys (protein I) or Asp-Pro (protein II) linkers were expressed in Escherichia coli cells. The fusion proteins were produced as insoluble inclusion bodies in the 20% yield of total cell protein. Protein I was cleaved by enterokinase. The solubility of protein I was increased by treating with Na-sulfite/Na-tetrathionate under denaturing conditions. Optimal conditions for efficient acidic hydrolysis of protein II at Asp-Pro bond were found. The hydrolysis products were separated by reversed-phase FPLC. The amount of tryptophan and cysteine residues in the enzyme obtained was estimated. The activity of HIV-I protease was determined using the chromogenic peptide. AlaArgVal NleNphGluAlaNleNH2 and a high-mol-wt substrate consisting of beta-galactosidase and a fragment of gag proteins, including p17-p24 processing site.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9100348     DOI: 10.1007/bf02785692

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  30 in total

1.  Human immunodeficiency viral protease is catalytically active as a fusion protein: characterization of the fusion and native enzymes produced in Escherichia coli.

Authors:  J Boutelje; A R Karlström; M G Hartmanis; E Holmgren; A Sjögren; R L Levine
Journal:  Arch Biochem Biophys       Date:  1990-11-15       Impact factor: 4.013

2.  Cleavage at aspartyl-prolyl bonds.

Authors: 
Journal:  Methods Enzymol       Date:  1977       Impact factor: 1.600

3.  Isolation of mutants of human immunodeficiency virus protease based on the toxicity of the enzyme in Escherichia coli.

Authors:  E Z Baum; G A Bebernitz; Y Gluzman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

4.  Reassessment of Ellman's reagent.

Authors:  P W Riddles; R L Blakeley; B Zerner
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor.

Authors:  C Debouck; J G Gorniak; J E Strickler; T D Meek; B W Metcalf; M Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

6.  Autoprocessing of the human immunodeficiency virus type 1 protease precursor expressed in Escherichia coli from a synthetic gene.

Authors:  V Valverde; P Lemay; J M Masson; B Gay; P Boulanger
Journal:  J Gen Virol       Date:  1992-03       Impact factor: 3.891

7.  Analysis of disulfide bonds in the Na+,K(+)-ATPase alpha-subunit.

Authors:  N M Gevondyan; V S Gevondyan; N N Modyanov
Journal:  Biochem Mol Biol Int       Date:  1993-02

8.  Isolation, renaturation, and formation of disulfide bonds of eukaryotic proteins expressed in Escherichia coli as inclusion bodies.

Authors:  B Fischer; I Sumner; P Goodenough
Journal:  Biotechnol Bioeng       Date:  1993-01-05       Impact factor: 4.530

9.  [Enteropeptidase and its use for cleavage of chimeric proteins].

Authors:  A G Mikhaĭlova; E D Shibanova; L D Rumsh; V K Antonov
Journal:  Bioorg Khim       Date:  1994 Aug-Sep

10.  Characterization and autoprocessing of precursor and mature forms of human immunodeficiency virus type 1 (HIV 1) protease purified from Escherichia coli.

Authors:  J E Strickler; J Gorniak; B Dayton; T Meek; M Moore; V Magaard; J Malinowski; C Debouck
Journal:  Proteins       Date:  1989
View more
  2 in total

1.  Optimizing HIV-1 protease production in Escherichia coli as fusion protein.

Authors:  Federica Volontè; Luciano Piubelli; Loredano Pollegioni
Journal:  Microb Cell Fact       Date:  2011-06-30       Impact factor: 5.328

2.  Cloning and Expression of Soluble Recombinant HIV-1 CRF35 Protease-HP Thioredoxin Fusion Protein.

Authors:  Asaad Azarnezhad; Zohreh Sharifi; Rahmatollah Seyedabadi; Arshad Hosseini; Behrooz Johari; Mahsa Sobhani Fard
Journal:  Avicenna J Med Biotechnol       Date:  2016 Oct-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.